Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Daniel Gurell"'
Publikováno v:
Translational Medicine Communications, Vol 9, Iss 1, Pp 1-11 (2024)
Abstract Background Immune Checkpoint Inhibitor (ICI) immunotherapy is most effective in immune effector cell infiltrated ‘hot’ tumor lesions, such as occurs in deficient mismatch repair, microsatellite instability high (dMMR/MSI-H) colorectal ca
Externí odkaz:
https://doaj.org/article/428ff7ec15474bee86c5e20ff1b5f8f9
Autor:
Howard W. Bruckner, Robert De Jager, Elisheva Knopf, Fred Bassali, Abe Book, Daniel Gurell, Van Nghiem, Myron Schwartz, Azriel Hirschfeld
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionRoutine blood tests are prognostic tests for patients with cholangiocarcinoma. New drug regimens may produce a median overall survival of 2 years or more.MethodsThis single practice, IRB-approved, phase II trial examines prognostic tests,
Externí odkaz:
https://doaj.org/article/2637638aaaa648f89987db28e96e8e32
Publikováno v:
PLoS ONE, Vol 17, Iss 11, p e0276492 (2022)
BackgroundPatients have difficult unmet needs when standard chemotherapy produces a median survival of less than 1 year or many patients will experience severe toxicities. Blood tests can predict their survival.MethodsAnalyses evaluate predictive blo
Externí odkaz:
https://doaj.org/article/3c944f62ff1d403c833c8697bc85b3a4
Autor:
AJ Book, Daniel Gurell, Azriel Hirschfeld, Howard W. Bruckner, Myron Schwartz, Robert De Jager, Van T. Nghiem, Fred Bassali, Shoshana Distenfeld
Publikováno v:
Journal of Clinical Oncology. 39:e16160-e16160
e16160 Background: Advanced (Adv) intrahepatic IH Cholangiocarcinoma BD trials found multi-drug, sequences (GFLIO) safely expand eligibility (El) for patients (pts) of all ages -/+ resistant Ca (R). Two series had response/survival (S) of 80% / > 2 y
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::525695372a42efff9fdf88b814c49f63
https://doi.org/10.1200/jco.2021.39.15_suppl.e16160
https://doi.org/10.1200/jco.2021.39.15_suppl.e16160
Autor:
Howard W. Bruckner, Robert De Jager, Shoshana Distenfeld, Fred Bassali, Azriel Hirschfeld, Van T. Nghiem, AJ Book, Noah Weinberger, Daniel Gurell
Publikováno v:
Journal of Clinical Oncology. 38:e16763-e16763
e16763 Background: Gemcitabine (G), 5-fluorouracil (F), leucovorin (L), irinotecan (I), and oxaliplatin (O), (GFLIO) is safe, employs moderate 1/2-1/3 dosages, offers expanded eligibility (0-2 ECOG PS; no age limit)). Each step reverse resistance (RR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b347d8f4b31d3b99db2712bb533d921
https://doi.org/10.1200/jco.2020.38.15_suppl.e16763
https://doi.org/10.1200/jco.2020.38.15_suppl.e16763
Publikováno v:
Anticancer Research. 38
Background/aim Bevacizumab (bev), when added to a moderate dose combination of previously failed cytotoxins, as a third- and fourth-line therapy for refractory gastric, cholangiocarcinoma, and ovarian cancers, produced high-quality responses. The reg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2df63c930bc47620bee3bb7f16ac73a
https://doi.org/10.21873/anticanres.12257
https://doi.org/10.21873/anticanres.12257
Autor:
Van T. Nghiem, Howard W. Bruckner, Azriel Hirschfeld, R. De Jager, N. Weinberger, Shoshana Distenfeld, Daniel Gurell, AJ Book
Publikováno v:
Journal of Geriatric Oncology. 10:S47-S48
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9bd81ce1b519efe01b7c9b2d5bb14684
https://doi.org/10.1016/s1879-4068(19)31196-8
https://doi.org/10.1016/s1879-4068(19)31196-8
Autor:
Fred Bassali, Shoshana Distenfeld, Howard W. Bruckner, Daniel Gurell, R. De Jager, Azriel Hirschfeld, N. Weinberger, Van T. Nghiem, AJ Book
Publikováno v:
Journal of Geriatric Oncology. 10:S39
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5eb219226f13e61ca1cf78ad47b308a
https://doi.org/10.1016/s1879-4068(19)31181-6
https://doi.org/10.1016/s1879-4068(19)31181-6
Publikováno v:
Cancer Research. 77:CT061-CT061
Background: High dose ascorbic acid has been reported to have in vitro anticancer activity. Low dose combination chemotherapy with GFLIP (gemcitabine, 5fu, leucovorin, irinotecan, oxaliplatin) is an effective regimen for patients with pancreatic canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d556ac3c0b33bbed6e1cc3f8e86a78e
https://doi.org/10.1158/1538-7445.am2017-ct061
https://doi.org/10.1158/1538-7445.am2017-ct061
Publikováno v:
The American Journal of Medicine. 119:839-842
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::837cda0b6e004407824632faf228a468
https://doi.org/10.1016/j.amjmed.2006.08.012
https://doi.org/10.1016/j.amjmed.2006.08.012